Crossmark

Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis

Published Online: 2021-10-10

Published Print: 2022-01

Authors

Mukozu, Takanori https://orcid.org/0000-0002-6716-2413
Nagai, Hidenari

Matsui, Daigo

Mohri, Kunihide

Watanabe, Go

Yoshimine, Naoyuki

Amanuma, Makoto

Kobayashi, Kojiro

Ogino, Yu

Matsukiyo, Yasushi

Matsui, Teppei

Daido, Yasuko

Wakui, Noritaka

Shinohara, Mie

Momiyama, Koichi

Higai, Koji

Igarashi, Yoshinori
License Information

Text and Data Mining valid from 2021-10-10

Version of Record valid from 2021-10-10
More Information

Article History

Received: 19 May 2021

Accepted: 27 September 2021

First Online: 10 October 2021

Declarations

:

: The authors have no relevant financial or non-financial interests to disclose.

: The study was approved by the ethics committee of Toho University Medical Center, Omori Hospital (approval number M20021) and was performed in accordance with the Declaration of Helsinki.

: All authors have approved the manuscript and agree with its submission to Cancer Chemotherapy and Pharmacology.

Document is current